Ampio Pharmaceuticals Inc. (NYSEAMERICAN: AMPE) announced today that it is awaiting a decision from the FDA to rule whether or not its last phase 3 clinical trial was to be considered a pivotal trial. The widely anticipated decision is expected by mid-December. The company had recently concluded a meeting with the FDA’s statisticians and will […]
